Stryker Sales Soar 11% on Acquisitions, But Impairments Hit Net Earnings

TL;DR

**SYK's M&A spree is fueling revenue growth, but watch out for those rising impairment charges – could signal integration headaches.**

AI Summary

Stryker Corporation reported robust net sales growth for the three and nine months ended September 30, 2025. Net sales increased by 10.25% to $6,057 million for the three-month period, up from $5,494 million in 2024, and by 11.05% to $17,945 million for the nine-month period, compared to $16,159 million in 2024. Despite this, net earnings saw a slight decrease for the nine-month period, falling to $2,397 million in 2025 from $2,447 million in 2024, a 2.04% decline. This was primarily driven by a significant increase in goodwill and other impairments, which surged from $21 million in the nine months of 2024 to $163 million in 2025, and higher selling, general and administrative expenses, which rose by $862 million to $6,424 million. The company also experienced a substantial increase in acquisitions, net of cash acquired, totaling $4,950 million for the nine months of 2025, up from $1,598 million in 2024, indicating aggressive inorganic growth. Cash and cash equivalents decreased by $396 million to $3,256 million at September 30, 2025, from $3,652 million at December 31, 2024, largely due to these acquisition activities. The Vascular business segment, bolstered by the Inari Medical, Inc. acquisition, showed exceptional growth, with net sales increasing by 59.57% to $525 million for the three months and 47.93% to $1,429 million for the nine months.

Why It Matters

Stryker's aggressive acquisition strategy, evidenced by the $4,950 million spent on acquisitions in the first nine months of 2025, signals a strong push for market share and product portfolio expansion, particularly with the Inari Medical, Inc. acquisition boosting the Vascular segment. This inorganic growth could lead to increased revenue and long-term competitive advantage for investors, but the significant rise in goodwill and other impairments to $163 million raises concerns about integration challenges or overvalued assets, potentially impacting future profitability. Employees might see shifts in roles and responsibilities due to these integrations, while customers could benefit from an expanded range of medical devices and solutions. The broader medical technology market will observe how Stryker's strategy impacts its competitive landscape against rivals like Johnson & Johnson and Medtronic, especially in high-growth areas like vascular and neurotechnology.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant increase in goodwill and other impairments, which jumped from $21 million in the nine months of 2024 to $163 million in 2025. This 676% increase suggests potential issues with recent acquisitions or a re-evaluation of asset values. Additionally, the substantial cash outflow of $4,950 million for acquisitions in the nine months of 2025, compared to $1,598 million in 2024, indicates a high-growth strategy that carries inherent integration and financial risks.

Analyst Insight

Investors should closely monitor future filings for further impairment charges and the successful integration of acquired businesses, particularly Inari Medical, Inc. While the strong revenue growth is positive, the increased debt and impairment risks warrant a cautious approach; consider holding existing positions but delay new investments until clearer signs of successful integration and reduced impairment risks emerge.

Financial Highlights

revenue

$17,945M

operating Margin

17.2%

total Debt

$14,845M

net Income

$2,397M

eps

$6.20

gross Margin

63.7%

cash Position

$3,256M

revenue Growth

+11.05%

Revenue Breakdown

Key Numbers

• $6,057M — Net sales for Q3 2025 (Increased by 10.25% from $5,494 million in Q3 2024)
• $17,945M — Net sales for nine months 2025 (Increased by 11.05% from $16,159 million in nine months 2024)
• $2,397M — Net earnings for nine months 2025 (Decreased by 2.04% from $2,447 million in nine months 2024)
• $163M — Goodwill and other impairments for nine months 2025 (Increased by 676% from $21 million in nine months 2024)
• $4,950M — Acquisitions, net of cash acquired for nine months 2025 (Increased from $1,598 million in nine months 2024)
• $3,256M — Cash and cash equivalents at Sep 30, 2025 (Decreased from $3,652 million at Dec 31, 2024)
• $525M — Vascular net sales for Q3 2025 (Increased by 59.57% from $329 million in Q3 2024)
• $1,429M — Vascular net sales for nine months 2025 (Increased by 47.93% from $966 million in nine months 2024)
• $6,424M — Selling, general and administrative expenses for nine months 2025 (Increased by $862 million from $5,562 million in nine months 2024)
• $14,845M — Long-term debt, excluding current maturities at Sep 30, 2025 (Increased from $12,188 million at Dec 31, 2024)

Key Players & Entities

• STRYKER CORP (company) — registrant
• Inari Medical, Inc. (company) — acquired company
• FASB (regulator) — Financial Accounting Standards Board
• SEC (regulator) — Securities and Exchange Commission
• Johnson & Johnson (company) — competitor
• Medtronic (company) — competitor
• Michigan (person) — State of incorporation
• New York Stock Exchange (company) — exchange where SYK is listed

FAQ

Industry Context

Stryker operates in the highly competitive medical technology industry, facing established players and innovative startups. Key trends include the increasing demand for minimally invasive surgical technologies, robotic surgery, and digital health solutions. Acquisitions are a common strategy for growth and market expansion within this sector.

Regulatory Implications

The medical device industry is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, product approvals, and post-market surveillance are critical. Changes in healthcare reimbursement policies and international trade regulations can also impact sales and profitability.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

Goodwill and other impairments

A charge taken when the carrying value of goodwill or other intangible assets on the balance sheet is deemed to be impaired, meaning its fair value is less than its book value. (A significant increase in this line item ($163M in 2025 vs $21M in 2024) negatively impacted net earnings.)

Acquisitions, net of cash acquired

The total cost of acquired businesses minus the cash and cash equivalents of the acquired businesses. This represents the net cash outflow for acquisitions. (A substantial increase ($4,950M in 2025 vs $1,598M in 2024) indicates aggressive inorganic growth, impacting cash position.)

Comprehensive income

Includes net earnings plus other comprehensive income (loss), which are unrealized gains or losses on certain investments and foreign currency translations. (Total comprehensive income decreased to $1,924M in the nine months of 2025 from $2,318M in 2024, largely due to negative foreign currency translation adjustments.)

Diluted EPS

Earnings per share calculated using the weighted average number of common shares outstanding, including the effect of all dilutive potential common shares (like stock options and convertible securities). (Diluted EPS for the nine months decreased to $6.20 in 2025 from $6.35 in 2024, reflecting the decline in net earnings.)

Year-Over-Year Comparison

Stryker demonstrated strong top-line growth with net sales increasing by 10.25% in Q3 and 11.05% year-to-date, driven by segments like Vascular. However, net earnings for the nine-month period declined by 2.04% due to a substantial rise in goodwill and other impairments and increased selling, general, and administrative expenses. The company also significantly ramped up its acquisition activity, leading to a decrease in cash and cash equivalents.

Key Financial Figures

• $0.10 — ere 382,423,648 shares of Common Stock, $0.10 par value, on September 30, 2025 . Do

Filing Documents

• syk-20250930.htm (10-Q) — 3659KB
• ex31i930202510q.htm (EX-31.I) — 9KB
• ex31ii930202510q.htm (EX-31.II) — 9KB
• ex32i930202510q.htm (EX-32.I) — 5KB
• ex32ii930202510q.htm (EX-32.II) — 5KB
• syk-20250930_g1.jpg (GRAPHIC) — 45KB
• 0000310764-25-000129.txt ( ) — 12816KB
• syk-20250930.xsd (EX-101.SCH) — 39KB
• syk-20250930_cal.xml (EX-101.CAL) — 77KB
• syk-20250930_def.xml (EX-101.DEF) — 233KB
• syk-20250930_lab.xml (EX-101.LAB) — 608KB
• syk-20250930_pre.xml (EX-101.PRE) — 415KB
• syk-20250930_htm.xml (XML) — 2687KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Stryker Corporation and Subsidiaries CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) Three Months Nine Months 2025 2024 2025 2024 Net sales $ 6,057 $ 5,494 $ 17,945 $ 16,159 Cost of sales 2,205 1,977 6,508 5,893 Gross profit $ 3,852 $ 3,517 $ 11,437 $ 10,266 Research, development and engineering expenses 410 377 1,222 1,108 Selling, general and administrative expenses 2,045 1,894 6,424 5,562 Amortization of intangible assets 189 159 543 467 Goodwill and other impairments 73 2 163 21 Total operating expenses $ 2,717 $ 2,432 $ 8,352 $ 7,158 Operating income $ 1,135 $ 1,085 $ 3,085 $ 3,108 Other income (expense), net ( 106 ) ( 42 ) ( 276 ) ( 144 ) Earnings before income taxes $ 1,029 $ 1,043 $ 2,809 $ 2,964 Income taxes 170 209 412 517 Net earnings $ 859 $ 834 $ 2,397 $ 2,447 Net earnings per share of common stock: Basic $ 2.25 $ 2.18 $ 6.27 $ 6.42 Diluted $ 2.22 $ 2.16 $ 6.20 $ 6.35 Weighted-average shares outstanding (in millions): Basic 382.4 381.1 382.1 380.9 Effect of dilutive employee stock compensation 4.3 4.5 4.4 4.5 Diluted 386.7 385.6 386.5 385.4 Cash dividends declared per share of common stock $ 0.84 $ 0.80 $ 2.52 $ 2.40 Anti-dilutive shares excluded from the calculation of dilutive employee stock options were de minimis in all periods. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Three Months Nine Months 2025 2024 2025 2024 Net earnings $ 859 $ 834 $ 2,397 $ 2,447 Other comprehensive income (loss), net of tax: Marketable securities — — — — Pension plans — ( 2 ) 2 ( 1 ) Unrealized gains (losses) on designated hedges 8 ( 27 ) 11 ( 28 ) Financial statement translation ( 12 ) ( 161 ) ( 486 ) ( 100 ) Total other comprehensive income (loss), net of tax

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE 1 - BASIS OF PRESENTATION General Information Management believes the accompanying unaudited Consolidated

Financial Statements contain all adjustments, including normal

Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," "us" or "our") on September 30, 2025 and the results of operations for the three and nine months 2025 . The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2024 . New Accounting Pronouncements Not Yet Adopted In September 2025 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2025-07 (Topics 815 and 606): Derivatives and Hedging: Derivatives Scope Refinements and Revenue from Contracts with Customers: Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. This update expands the scope exception in Topic 815 to certain non- exchange-traded contracts for which settlement is based on operations or activities specific to one of the parties to the contract. The update is effective for fiscal years beginning after December 15, 2026 including interim periods within those fiscal years. Early adoption is permitted. We are evaluating if the ASU will have an impact on our Consolidated Financial Statements. In September 2025 the FASB issued ASU 2025-06 (Subtopic 350-40): Intangibles - Goodwill and Other - Internal-Use Software: Targeted Improvements to the Accounting for Internal- Use Software. This update clarifies and modernizes the accounting for costs related to internal-use software by removing all references to project stages and clarifying that the probable- to-complete threshold is not met if significant development uncertainty exists. The update is effective for fiscal years beginning after December 15, 2027 including interim periods within those fiscal years. Ear

Financial Statements

Financial Statements. In July 2025 the FASB issued ASU 2025-05 (Topic 326): Financial Instruments - Credit Losses: Measurement of Credit Losses for Accounts Receivable and Contract Assets. This update provides a practical expedient allowing entities to assume that current conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounting for under Accounting Standards Codification 606, Revenue from Contracts with Customers . The update is effective for fiscal years beginning after December 15, 2025 including interim periods within those fiscal years. Early adoption is permitted. We are evaluating if the ASU will have an impact on our Consolidated

Financial Statements

Financial Statements. In November 2024 the FASB issued ASU 2024-03 (Subtopic 220-40): Income Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosures which requires disaggregation of certain expense captions into specified categories in disclosures within the Notes to the Consolidated

Financial Statements. The new disclosure requirements are

Financial Statements. The new disclosure requirements are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are evaluating these new expanded disclosure requirements. In December 2023 the FASB issued ASU 2023-09 (Topic 740): Income Taxes: Improvements to Income Tax Disclosures which expands the existing rules on income tax disclosures. This update requires entities to disclose specific categories in the tax rate reconciliation, provide additional information for reconciling items that meet a quantitative threshold and disclose additional information about income taxes paid on an annual basis. The new disclosure requirements are effective for fiscal years beginning after December 15, 2024 and we will adopt this ASU in the fourth quarter 2025. We evaluate all ASUs issued by the FASB for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements. NOTE 2 - REVENUE RECOGNITION Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2024 . We disaggregate our net sales by business and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. In the first quarter 2025 we changed the name of our Neurovascular business to Vascular due the acquisition of Inari Medical, Inc. (Inari). In the fourth quarter 2024 we reorganized our Spine business to align with certain updates to our internal reporting structure. The spine enabling technologies portfolio (Enabling Technologies) was reclassified to Other Orthopaedics and Spine, the interventional spine (IVS) portfolio was reclassified to Neuro